TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, announced the publication of a peer-reviewed article in Cancers reporting preclinical results for its lead therapeutic candidate, TTX-MC138, in a model of breast cancer bone metastasis. The study found that TTX-MC138 accumulated in metastatic bone lesions following systemic administration, reduced expression of microRNA-10b (miR-10b), increased expression of the downstream tumor-suppressor target HOXD10, and produced significant survival benefits compared with controls. Repeated dosing was well tolerated with no observed systemic toxicity.
The findings further support TransCode's approach of inhibiting miR-10b using its proprietary oligonucleotide nanotechnology and suggest potential applicability across additional metastatic disease settings. This is particularly important because bone metastasis is a common and serious complication of breast cancer, often leading to significant morbidity and mortality. Current treatments are largely palliative, and there is a high unmet need for therapies that can specifically target metastatic cells.
The study's results indicate that TTX-MC138 could potentially be a novel therapeutic option for patients with metastatic breast cancer, especially those with bone involvement. By targeting miR-10b, which is known to promote metastasis, the therapy may prevent the spread of cancer and improve survival outcomes. The favorable safety profile observed in this study is also encouraging for future clinical development.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
The publication of these findings in a peer-reviewed journal adds to the growing body of evidence supporting TTX-MC138's mechanism of action and therapeutic potential. It also underscores the promise of RNA-based therapeutics in oncology, an area that has gained significant attention in recent years.
For more information, see the full press release at https://ibn.fm/E6gbq. The latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ.
